Stocks · News reference
ImmunityBio shares are trading higher after the company announced that the Emirates Drug Establishment of the United Arab Emirates has granted Marketing Authorization for ANKTIVA across two indications.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 30, 2026, 6:49 PM
- Checked
- Jul 30, 2026, 6:49 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
ImmunityBio shares are trading lower after the company reported a wider GAAP net loss for the second quarter reflecting a sharp increase in expenses.
Read original at benzingaImmunityBio Q2 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $51.240M Beat $49.700M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 20 percent increase over losses of $(0.10) per share from the
Read original at benzinga8-K filing — ImmunityBio, Inc. (IBRX)
Filed: 2026-08-04 AccNo: 0001326110-26-000077 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar